Safety evaluation of riociguat: insights from FAERS and VigiAccess databases, and establishment of pharmacist management framework
A comprehensive understanding of the safety profile of riociguat is essential for optimizing patient management. We analyzed riociguat-associated adverse event (AE) reports from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) and VigiAccess databases. Gender-specific AEs, ser...